Valiant Laboratories Ltd Stock Price Today (NSE: VALIANTLAB)

Valiant Laboratories Ltd

VALIANTLABPharmaceuticals
66.63+0.72 (+1.09%)
Market Closed

Fundamental Score

...

Valiant Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Valiant Laboratories Ltd share price today is 66.63, up +1.09% on NSE/BSE as of 17 June 2026. Valiant Laboratories Ltd (VALIANTLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 367.80 (Cr). The 52-week high for VALIANTLAB share price is 120.50 and the 52-week low is 49.51. At a P/E ratio of 72.54x, VALIANTLAB is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of -1.43% and a debt-to-equity ratio of 0.17.

Valiant Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
83.70
Low
66.63
Volume
29.8K
Change
+1.99%

Valiant Laboratories Ltd share price chart: 1.99% return over the past month. 52-week high ₹120.50, 52-week low ₹49.51.

Valiant Laboratories Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
80.8081.4976.3076.762.18L (Cr)
77.4481.3076.0080.312.22L (Cr)
80.0280.0277.0077.4418.71K (Cr)
79.0081.9078.0080.0212.97K (Cr)
80.0081.6877.9078.7446.09K (Cr)
76.8878.0076.0077.9022.19K (Cr)
75.9777.2575.0076.886.43K (Cr)
77.9077.9075.0075.978.35K (Cr)
75.0476.9074.0576.5416.31K (Cr)
75.4176.9573.0075.0430.65K (Cr)

Valiant Laboratories Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
77.4481.4976.0076.76-0.88%
79.3882.2073.0077.44-2.44%
54.0083.7053.9977.82+44.11%
53.1063.7049.5151.62-2.79%
57.0068.5056.0057.28+0.49%
70.3575.4056.5358.75-16.49%
66.2979.9063.8670.00+5.60%
82.0085.2065.3066.34-19.10%
83.1289.8079.3882.74-0.46%
87.1394.9581.0081.48-6.48%
94.00100.9885.6187.09-7.35%
113.21120.5086.6091.63-19.06%

Returns & Performance

Poor

Return on Equity (ROE)

-1.43%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

-0.95%

Returns generated on total capital deployed

Oper. Profit Margin (5Y Avg)

N/A

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Valiant Laboratories Ltd Valuation Check

Poor

Price to Earnings (P/E)

72.54x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

74.94%

% shares held by company founders/management

Poor

FII Holding

0.02%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

104.22%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

115.08%

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.17x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

17.53x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

N/A

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Valiant Laboratories Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of VALIANTLAB across key market metrics for learning purposes.

Positive Indicators

6 factors identified

Robust Profit Growth (104.22%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (115.08%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Conservative Debt Levels (D/E: 0.17)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (17.53x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Balanced Promoter Holding (74.94%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

5 factors identified

Below-Average Return on Equity (-1.43%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (-0.95%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Premium Valuation Risk (P/E: 72.54x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Limited Institutional Interest (FII+DII: 0.02%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Valiant Laboratories Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Valiant Laboratories Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
31.9/100
67
₹367.80
72.5
Average
-1.43%
Poor
-0.95%
Poor
0.2
Excellent
0.00%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Valiant Laboratories Ltd PE Ratio History

Historical price-to-earnings ratio for VALIANTLAB — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20240.12₹111.13921x
FY 20236.19₹173.2028x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Valiant Laboratories Ltd Quarterly Performance

Latest quarterly metrics for VALIANTLAB — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

115.08%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

104.22%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Valiant Laboratories Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for VALIANTLAB — calculated from daily price history

50RSI 14
Neutral — RSI 50

Momentum is balanced — neither overbought nor oversold.

SMA 50
68
▼ Price below SMA 50 — Short-term bearish
SMA 200
73
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
54K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Valiant Laboratories Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Valiant Laboratories Ltd (VALIANTLAB) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Valiant Laboratories Ltd

About VALIANTLAB (Valiant Laboratories Ltd)

Valiant Laboratories Ltd is a dynamic pharmaceutical company carving a niche in the production and distribution of high-quality active pharmaceutical ingredients (APIs) and special...ty chemicals. Strategically headquartered in India, Valiant Laboratories serves both domestic and international markets with a commitment to excellence and stringent quality control. The company’s strength lies in its ability to manufacture essential pharmaceutical components, building a reliable supply chain for its partners across the globe. With a focus on continuous improvement and innovative manufacturing processes, Valiant Laboratories stands as a trusted source for pharmaceutical solutions, contributing to the advancement of healthcare through its dedication to producing dependable and effective ingredients. At the heart of Valiant Laboratories' product portfolio is the versatile paracetamol, manufactured in compliance with a comprehensive range of pharmacopoeial standards including Indian, British, European, and United States specifications. This ensures the company meets diverse regulatory requirements and customer needs worldwide. Beyond paracetamol, Valiant Laboratories expands its offerings with a selection of specialty chemicals designed to cater to specific market demands. This dual focus allows the company to operate within a broad scope of the pharmaceutical industry, catering to both established needs and emerging opportunities. Through its commitment to stringent quality standards and comprehensive product range, Valiant Laboratories is recognized as a provider of reliable pharmaceutical ingredients. Originally established as Bharat Chemicals, Valiant Laboratories evolved to embody a renewed commitment to innovation and global reach. The strategic name change signifies a transformational phase, reflecting the company's ambitious vision and dedication to expanding its presence in the international pharmaceutical landscape. Today, Valiant Laboratories operates with a forward-thinking approach, emphasizing research and development to stay ahead of market trends and deliver cutting-edge solutions. By continuously investing in infrastructure and technology, Valiant Laboratories aims to reinforce its position as a key player in the API manufacturing sector, ultimately contributing to the improved health and wellbeing of individuals worldwide.

Company Details

Symbol:VALIANTLAB
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Santosh Shantilal Vora
MD & Executive Director
Mr. Paresh Shashikant Shah
Whole-Time Director & CFO
Ms. Kiran Mudaliar
Assistant Manager of Accounts

VALIANTLAB Share Price: Frequently Asked Questions

What is the current share price of Valiant Laboratories Ltd?

Valiant Laboratories Ltd (VALIANTLAB) trades at ₹66.63 on NSE and BSE. Market cap ₹367.80 (Cr). Educational data only.

What is the P/E ratio of Valiant Laboratories Ltd?

Valiant Laboratories Ltd has a P/E of 72.54x vs industry average 31.77x.

What is the Bull Run score for Valiant Laboratories Ltd?

Valiant Laboratories Ltd has a Bull Run score of 31.9/100 based on 25+ financial parameters.

Does Valiant Laboratories Ltd pay dividends?

Valiant Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Valiant Laboratories Ltd?

Valiant Laboratories Ltd has ROE of -1.43%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Valiant Laboratories Ltd?

Valiant Laboratories Ltd has debt-to-equity of 0.17.

Is Valiant Laboratories Ltd a good investment?

Bull Run gives Valiant Laboratories Ltd a score of 31.9/100. This is not investment advice — consult a SEBI-registered advisor.